Key findings: CagriSema achieved up to 23% weight loss at 84 weeks Tirzepatide showed numerical superiority (~25.5%) The trial did not meet non-inferiority vs tirzepatide Clinical interpretation: Despite not meeting the primary endpoint, an important signal emerges: targeting multiple biological pathways remains a compelling strategy Why this matters: Reinforces obesity as a complex neuroendocrine disease Supports the concept that multi-hormonal approaches may better impact the defended weight set point Moves the field closer to precision, mechanism-based therapies Safety: Consistent with the GLP-1 class Mainly gastrointestinal adverse events, generally mild to moderate and transient Whats next: Ongoing development with higher-dose CagriSema Expansion of the REDEFINE program FDA decision expected by late 2026 Take-home message: The future of obesity treatment lies not in a single pathway, but in strategically combining mechanisms to sustainably shift weight biology

Dual Treatments Dual GLP- 1/GIP Receptor co-agonist Tirzepatide Tirzepatide is the first dual GLP- 1/GIP receptor co-agonist [98]
Another time, she was turned down only to watch men get funding with a far inferior idea
The majority of them are linear, synthetic, protein-derived, and amphipathic CPPs (Xie et al., 2020)
We at Bayview Pharmacy are committed to providing safe and effective compound formulations and are more than happy to discuss patient-specific needs and concerns
What is GLP-1 and how does it support appetite and metabolic health GLP-1 Metabolic Support Curb cravings | Metabolic and microbiome balance | Stimulates GLP-1 hormone production Curb cravings Metabolic and microbiome balance Stimulates GLP-1 hormone production Up to 85% hunger reduction in 60 days With chromium & biotin GLP-1 prescription medications versus natural approaches It's important to distinguish between pharmaceutical GLP-1 medications and natural ways to support GLP-1 function